Navigation Links
New Evidence Published in Muscle and Nerve on Measuring 6-Minute Walk Distance in Duchenne Muscular Dystrophy
Date:8/26/2013

ient population that are in the decline phase of walking ability and would best demonstrate benefit in a 48-week trial. When we looked back at the subgroup of 61 patients from our completed Phase 2b trial that fit the inclusion criteria of the current trial, they showed an average 50 meter improvement in ambulation as measured in the 6-minute walk distance from patients on placebo. We anticipate that the Phase 3 trial will complete enrollment mid-2014."

This report in Muscle & Nerve represents an evaluation of the largest multicenter dataset collected to date to determine the reliability and concurrent validity of the 6MWT and other clinical endpoints in DMD. In addition, the research assesses the distribution-based MCID (minimal clinically important difference) for 6MWD and other commonly-employed functional endpoints (eg. timed function tests and quantitative knee extension strength measures) as well as the 6MWD, which is the most common primary endpoint for ambulatory DMD clinical trials. Moreover, baseline walking ability, as measured by the 6MWD was found to be predictive of time to ≥10% worsening in function, a clinically meaningful milestone, in DMD.

The research findings confirm that the 6MWT is a safe and feasible measure of walking ability in DMD and a valid primary outcome measure for ambulatory DMD clinical trials. In addition, the data supports the clinically meaningful change in walking ability, as measured by 6MWT, to be in the range of 20 to 30 meters, which can serve as a targeted treatment effect in 12-month trials in ambulatory DMD.

About the Publications           
The natural history data were derived from the placebo arm of a Phase 2b, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of ataluren in ambulatory male patients with nonsense mutation DMD aged ≥5 years
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
2. Publication of PrEP Trial Data Provides Clear Evidence that PrEP Works for Men and Women
3. 90 Presentations at Leading Radiation Oncology Meeting Demonstrate the Breadth and Depth of Clinical Evidence for Accuray Technologies
4. Annai Systems And ThoughtWorks Develop Evidence Engine For The Clearity Foundation To Individualize Options For Treatment Of Ovarian Cancer
5. Frost & Sullivan: Clinical Trial-based Evidence Vital to Obtain Venture Capital Funding for Wireless Patient Monitoring Technologies
6. Zynx Health Launches Unrivaled MEDITECH Integration for Evidence-based Care Plans
7. J.D. Power and Associates Reports: Evidence that Relationship Marketing Still Matters in Oncology Pharmaceutical Sales
8. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
9. New Published Guidelines to Help Physicians Diagnose and Treat Lupus Kidney Disease
10. New Data from Silences Atu027 Anticancer Trial Published at ASCO
11. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Aug. 4, 2015  Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: ... epigenetic drivers of cancer, will be presenting at the 2015 ... 1:55 p.m. ET (10:55 a.m. PT) in New ... president and CEO of Mirati, will provide a corporate overview. ... be accessible on the "Investors" page of Mirati,s corporate website ...
(Date:8/4/2015)... MADISON, Wis. , Aug. 4, 2015 /PRNewswire/ ... an agreement with Restore Health, a company specializing ... of a double-blind clinical trial, designed to evaluate ... drug in development to treat Attention-deficit/hyperactivity disorder (ADHD). ... Ironshore. Restore Health originally partnered with ...
(Date:8/3/2015)...  Luminex Corporation (NASDAQ: LMNX ) today announced ... 2015.  Financial and operating highlights for the quarter include ... revenue by 6 percent to $58.9 million, over the ... 2015 assay revenue by 22 percent to $24.2 million ... , Increased Q2 2015 royalty revenue by 17 percent ...
Breaking Medicine Technology:Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 3Luminex Corporation Reports Record 2nd Quarter 2015 Results 4Luminex Corporation Reports Record 2nd Quarter 2015 Results 5Luminex Corporation Reports Record 2nd Quarter 2015 Results 6Luminex Corporation Reports Record 2nd Quarter 2015 Results 7Luminex Corporation Reports Record 2nd Quarter 2015 Results 8Luminex Corporation Reports Record 2nd Quarter 2015 Results 9Luminex Corporation Reports Record 2nd Quarter 2015 Results 10Luminex Corporation Reports Record 2nd Quarter 2015 Results 11Luminex Corporation Reports Record 2nd Quarter 2015 Results 12Luminex Corporation Reports Record 2nd Quarter 2015 Results 13Luminex Corporation Reports Record 2nd Quarter 2015 Results 14Luminex Corporation Reports Record 2nd Quarter 2015 Results 15Luminex Corporation Reports Record 2nd Quarter 2015 Results 16
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... the launch of a new product suite designed to provide pharmaceutical and healthcare ... trends based on multi-sourced and cross-referenced data from regulatory filings (including the FDA ...
(Date:8/4/2015)... ... August 04, 2015 , ... Armadale Capital ... announced the closing of a $118 million FHA-insured loan modification refinancing for Johnston ... Smithfield and Clayton, North Carolina. JHSC is a joint venture of Johnston ...
(Date:8/4/2015)... ... August 04, 2015 , ... Updated enrollment data on the top U.S. health ... be accessed at http://www.AISHealth.com . The data is free to all registered users ... tables and charts on the website’s “Data” section include:, , ...
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental ... and crafts, toys, novelties, and school supplies, has developed engaging and affordable teacher ... exclusive collection includes student rewards, classroom decorations, crafts and educational resources featuring ...
(Date:8/4/2015)... ... 2015 , ... Mercy Health (formerly Catholic Health Partners) – a Catholic healthcare ministry serving Ohio ... Well videos to preparing high school athletes for fall sports. , In a concise video ... , What steps to take to help prevent injuries , ...
Breaking Medicine News(10 mins):Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 2Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 3Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:Mercy Health Video Provides Helpful Information for High School Athletes 2
... HealthDay Reporter , TUESDAY, Sept. 6 (HealthDay News) ... as ibuprofen during the first stage of their pregnancy ... suggests. "We,re seeing a 2.4-fold increased risk ... pregnancy," said Anick Berard, senior author of a paper ...
... U.S. Food and Drug Administration (FDA) clears the path for ... estimating the risk of ovarian cancer in women with a ... and use of a combination of blood tests for proteins ... (ROMA). Research demonstrates that examining levels of HE4 and CA125 ...
... PARK, Md. - Amid ongoing concerns about E. coli, ... take a unique approach to make imports bound for ... those foods intensive, hands-on lab training in U.S. government ... "The more we can get foreign food facilities ...
... German . The stomach bacterium Helicobacter pylori ... gastric cancer, the third most common cause of cancer-related deaths in ... identified a mechanism of Helicobacter pylori that damages the DNA of ... transformation. Gastric cancer is one of the most common and ...
... cells is an effective treatment for patients with malignant ... cells are crucial to the outcome. Researchers from Lund ... the quality of the transplanted cells using ultrasound for ... blood stem cell transplant is often the only treatment ...
... , This release is available in German . ... they react with a suitable behavioural response and do not ... is the case, for example, with patients who suffer from ... from the Max Planck Institute of Psychiatry have discovered two ...
Cached Medicine News:Health News:NSAIDs May Raise Miscarriage Risk: Study 2Health News:NSAIDs May Raise Miscarriage Risk: Study 3Health News:FDA clears biomarker test for ovarian cancer 2Health News:FDA clears biomarker test for ovarian cancer 3Health News:For safer food imports, Teach foreign lab workers US requirements 2Health News:For safer food imports, Teach foreign lab workers US requirements 3Health News:Stomach bacterium damages human DNA 2Health News:Ultrasound improves stem cell transplants 2Health News:Control of fear in the brain decoded 2Health News:Control of fear in the brain decoded 3
... Vitoss engineered to ... porosity and structure. -TCP ... well in spinal arthrodesis ... defects due to trauma ...
... is a synthetic porous ceramic graft material composed ... mineral phase that comprises 70% of human bone. ... scaffold that allows the attachment of bone forming ... networks within granules as well as between each ...
Weitlaner-Locktite retractors, blunt, 11 cm total length....
Baby Weitlaner retractor, blunt, 4"....
Medicine Products: